<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="RevAutoimmun RevAutoimmunity Reviews1568-99721873-0183Elsevier B.V. S1568-9972(20)30078-1 doi: 10.1016/j.autrev.2020.102523102523 : Article COVID-19" exact="infection" post="and rheumatoid arthritis: Faraway, so close! FavalliEnnio Giulioenniofavalli@me.comaâ�ŽIngegnoliFrancescaabDe LuciaOrazioaCincinelliGilbertobCimazRolandobcCaporaliRobertoab[a],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="centre remains active. Abstract The outbreak of the new coronavirus" exact="infections" post="COVID-19 in December 2019 in China has quickly become"/>
 <result pre="lack of specific anti-viral therapies, the current management of severe" exact="acute" post="respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though"/>
 <result pre="of specific anti-viral therapies, the current management of severe acute" exact="respiratory" post="syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several"/>
 <result pre="specific anti-viral therapies, the current management of severe acute respiratory" exact="syndrome" post="coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds"/>
 <result pre="certainly conditioning the treatment strategy of a complex disorder as" exact="rheumatoid arthritis" post="(RA), whose infectious risk is increased compared to the"/>
 <result pre="conditioning the treatment strategy of a complex disorder as rheumatoid" exact="arthritis" post="(RA), whose infectious risk is increased compared to the"/>
 <result pre="strategy of a complex disorder as rheumatoid arthritis (RA), whose" exact="infectious" post="risk is increased compared to the general population because"/>
 <result pre="because of an overall impairment of immune system typical of" exact="autoimmune diseases" post="combined with the iatrogenic effect generated by corticosteroids and"/>
 <result pre="drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2" exact="infection" post="is leading to consider some anti-rheumatic drugs as potential"/>
 <result pre="order to optimize the current approach to RA patients. Keywords" exact="Rheumatoid arthritis" post="COVID-19 Treatment DMARDs Cytokine release syndrome Coronavirus 1 Introduction"/>
 <result pre="to optimize the current approach to RA patients. Keywords Rheumatoid" exact="arthritis" post="COVID-19 Treatment DMARDs Cytokine release syndrome Coronavirus 1 Introduction"/>
 <result pre="RA patients. Keywords Rheumatoid arthritis COVID-19 Treatment DMARDs Cytokine release" exact="syndrome" post="Coronavirus 1 Introduction In December 2019 a new type"/>
 <result pre="Coronavirus 1 Introduction In December 2019 a new type of" exact="pneumonia" post="supported by a novel member of the coronoviridae family"/>
 <result pre="a novel member of the coronoviridae family named SARS-CoV-2 (severe" exact="acute" post="respiratory coronavirus 2 syndrome) developed from Wuhan Province in"/>
 <result pre="novel member of the coronoviridae family named SARS-CoV-2 (severe acute" exact="respiratory" post="coronavirus 2 syndrome) developed from Wuhan Province in China"/>
 <result pre="different virus with ~80% nucleotide identity with SARS-CoV-1 [2]. The" exact="disease" post="caused by SARS-CoV-2 is characterized by dry cough, fever,"/>
 <result pre="characterized by dry cough, fever, dyspnea and fatigue, accompanied by" exact="lymphopenia" post="[[3], [4], [5], [6]]. In more severe cases (apparently"/>
 <result pre="picture may become more complicated by the onset of interstitial" exact="pneumonia" post="with alveolar damage, which clinically can lead to severe"/>
 <result pre="pneumonia with alveolar damage, which clinically can lead to severe" exact="Acute" post="Respiratory Distress Syndrome (ARDS) and even death [7]. Since"/>
 <result pre="with alveolar damage, which clinically can lead to severe Acute" exact="Respiratory" post="Distress Syndrome (ARDS) and even death [7]. Since the"/>
 <result pre="damage, which clinically can lead to severe Acute Respiratory Distress" exact="Syndrome" post="(ARDS) and even death [7]. Since the initial outbreak,"/>
 <result pre="which led the World Health Organization (WHO) to declare the" exact="disease" post="now called COVID-19 a Public Health Emergency of International"/>
 <result pre="is absolutely crucial. On the one hand, the rapid and" exact="uncontrolled" post="spread of the epidemic can clearly generate even more"/>
 <result pre="of the epidemic can clearly generate even more concerns in" exact="rheumatic" post="patients, which are intrinsically characterized by an increased infectious"/>
 <result pre="in rheumatic patients, which are intrinsically characterized by an increased" exact="infectious" post="risk due to the disease itself and to the"/>
 <result pre="intrinsically characterized by an increased infectious risk due to the" exact="disease" post="itself and to the iatrogenic effect of immunosuppressive agents"/>
 <result pre="other hand, the growing knowledge about the pathogenesis of SARS-CoV-2" exact="infection" post="is leading to the introduction of drugs commonly used"/>
 <result pre="the introduction of drugs commonly used for the treatment of" exact="rheumatoid arthritis" post="(RA) even for the management of more complex cases"/>
 <result pre="introduction of drugs commonly used for the treatment of rheumatoid" exact="arthritis" post="(RA) even for the management of more complex cases"/>
 <result pre="alongside antiviral drugs, in protocols for the treatment of COVID-19" exact="pneumonia" post="[10]. In addition, the use of interleukin 6 (IL-6)"/>
 <result pre="consequent ARDS occurring in the most aggressive patterns of SARS-CoV" exact="infection" post="[11]. Therefore, waiting for observational data on the incidence"/>
 <result pre="purpose of this review is to provide an overview on" exact="viral" post="infectious risk in RA patients, with a particular focus"/>
 <result pre="of this review is to provide an overview on viral" exact="infectious" post="risk in RA patients, with a particular focus on"/>
 <result pre="this context of health emergency. 2 The pathophysiology of COVID-19" exact="infection" post="Coronaviruses are the largest viruses with a positive-sense single-stranded-RNA"/>
 <result pre="receptor for SARS-CoV2 envelope spike glycoprotein [12]. ACE2 is a" exact="type I" post="membrane protein expressed on cells in the kidney, heart,"/>
 <result pre="protein expressed on cells in the kidney, heart, gastrointestinal tract," exact="blood vessels," post="and, importantly, lung AT2 alveolar epithelial cells, which are"/>
 <result pre="heart, gastrointestinal tract, blood vessels, and, importantly, lung AT2 alveolar" exact="epithelial" post="cells, which are particularly prone to viral infection [13]."/>
 <result pre="lung AT2 alveolar epithelial cells, which are particularly prone to" exact="viral infection" post="[13]. SARS-CoV-2 infection leads to the downregulation of ACE2"/>
 <result pre="AT2 alveolar epithelial cells, which are particularly prone to viral" exact="infection" post="[13]. SARS-CoV-2 infection leads to the downregulation of ACE2"/>
 <result pre="cells, which are particularly prone to viral infection [13]. SARS-CoV-2" exact="infection" post="leads to the downregulation of ACE2 expression, thus resulting"/>
 <result pre="the stimulation of type 1a angiotensin II receptor (AGTR1A) increases" exact="pulmonary" post="vascular permeability, thus potentially explaining the increased lung damage"/>
 <result pre="stimulation of type 1a angiotensin II receptor (AGTR1A) increases pulmonary" exact="vascular" post="permeability, thus potentially explaining the increased lung damage when"/>
 <result pre="mechanism of action, it has been postulated that subjects with" exact="diabetes mellitus" post="or hypertension using ACE-inhibitors or angiotensin receptor blockers may"/>
 <result pre="it has been postulated that subjects with diabetes mellitus or" exact="hypertension" post="using ACE-inhibitors or angiotensin receptor blockers may have an"/>
 <result pre="blockers may have an increase of both the risk of" exact="infection" post="and the severity of COVID-19 [15]. As only scarce"/>
 <result pre="of the genetic predisposition for an increased risk of SARS-CoV-2" exact="infection" post="due to ACE2 polymorphisms that have been linked to"/>
 <result pre="due to ACE2 polymorphisms that have been linked to hypertension," exact="diabetes mellitus," post="and cerebral stroke, especially in Asian populations [15]. The"/>
 <result pre="polymorphisms that have been linked to hypertension, diabetes mellitus, and" exact="cerebral" post="stroke, especially in Asian populations [15]. The viral RNA"/>
 <result pre="mellitus, and cerebral stroke, especially in Asian populations [15]. The" exact="viral" post="RNA genome is released into the cytoplasm, and the"/>
 <result pre="polyproteins, transcription of the sub-genomic RNAs and replication of the" exact="viral" post="genome [17]. Progression to ARDS is associated with the"/>
 <result pre="upregulation of pro-inflammatory cytokines and chemokines, known as Cytokines Release" exact="Syndrome" post="(CRS), with a pattern very similar to that of"/>
 <result pre="Syndrome (CRS), with a pattern very similar to that of" exact="secondary" post="haemophagocytic lymphohistiocytosis (sHLH). In adults, sHLH is an under-recognized,"/>
 <result pre="haemophagocytic lymphohistiocytosis (sHLH). In adults, sHLH is an under-recognized, hyperinflammatory" exact="syndrome" post="characterized by a massive and fatal hypercytokinaemia with multiorgan"/>
 <result pre="and fatal hypercytokinaemia with multiorgan failure, most commonly triggered by" exact="viral" post="infections [18,19]. Main clinical features of sHLH include unremitting"/>
 <result pre="fatal hypercytokinaemia with multiorgan failure, most commonly triggered by viral" exact="infections" post="[18,19]. Main clinical features of sHLH include unremitting fever,"/>
 <result pre="features of sHLH include unremitting fever, hyperferritinaemia and cytopenias, and" exact="pulmonary" post="involvement (including ARDS) occurring in approximately 50% of patients"/>
 <result pre="a number of cytokines (interleukin-1Î² [IL-1Î²], IL-2, IL-6, IL-7, IL-8," exact="tumor" post="necrosis factor-Î± [TNF]) and chemokines (CXC-chemokine ligand 10 [CXCL10]"/>
 <result pre="unmet needs regarding COVID-19 infection. 3 Is the risk of" exact="viral infection" post="increased in RA patients? The relationship between RA and"/>
 <result pre="needs regarding COVID-19 infection. 3 Is the risk of viral" exact="infection" post="increased in RA patients? The relationship between RA and"/>
 <result pre="infection increased in RA patients? The relationship between RA and" exact="infectious diseases" post="is very complex and can be interpreted in two"/>
 <result pre="On the one hand, in fact, the potential role of" exact="external" post="microorganisms in producing acute and chronic arthritis in the"/>
 <result pre="in fact, the potential role of external microorganisms in producing" exact="acute" post="and chronic arthritis in the form of either the"/>
 <result pre="the potential role of external microorganisms in producing acute and" exact="chronic" post="arthritis in the form of either the direct colonization"/>
 <result pre="potential role of external microorganisms in producing acute and chronic" exact="arthritis" post="in the form of either the direct colonization of"/>
 <result pre="colonization of the joints by the pathogen or the aberrant" exact="autoimmune" post="reaction produced by the host response to the infection"/>
 <result pre="aberrant autoimmune reaction produced by the host response to the" exact="infection" post="is well known [23,24]. Few studies have investigated a"/>
 <result pre="known [23,24]. Few studies have investigated a potential link between" exact="respiratory" post="viral infections and the development of RA [25] and"/>
 <result pre="[23,24]. Few studies have investigated a potential link between respiratory" exact="viral" post="infections and the development of RA [25] and in"/>
 <result pre="Few studies have investigated a potential link between respiratory viral" exact="infections" post="and the development of RA [25] and in particular"/>
 <result pre="of incident RA [26]. In addition, in patients with overt" exact="inflammatory arthritis," post="infections are a major concern as they can contribute"/>
 <result pre="RA [26]. In addition, in patients with overt inflammatory arthritis," exact="infections" post="are a major concern as they can contribute to"/>
 <result pre="infections are a major concern as they can contribute to" exact="disease" post="flares [[27], [28], [29]]. On the other hand, RA"/>
 <result pre="other hand, RA patients carry a documented increased risk of" exact="infection" post="compared with the general population. A population-based study by"/>
 <result pre="95% CI 1.41â€&quot;1.65) and hospitalized (RR 1.88, 95% CI 1.71â€&quot;2.07)" exact="infections" post="[30]. Similarly, a prospective cohort study conducted on 2108"/>
 <result pre="polyarthritis reported a 2- to 4-fold increased risk of hospitalized" exact="infection" post="compared to healthy population [31]. This trend is primarily"/>
 <result pre="a general impairment of the immune system typical of all" exact="autoimmune" post="disorders and strictly dependent on the degree of disease"/>
 <result pre="all autoimmune disorders and strictly dependent on the degree of" exact="disease" post="activity. In fact, it has been demonstrated by an"/>
 <result pre="the US CORRONA registry that each 0.6 unit increase in" exact="Disease" post="Activity Score 28 (DAS28) corresponded to a 25% increased"/>
 <result pre="Score 28 (DAS28) corresponded to a 25% increased rate of" exact="infections" post="requiring hospitalization (Incident rate ratio [IRR] 1.25, pÂ =Â"/>
 <result pre="pÂ =Â .03) and a 4% increased rate of outpatient" exact="infections" post="(IRR 1.04, pÂ =Â .01) [32]. In addition, a"/>
 <result pre="from the same registry showed that the risk of serious" exact="infections" post="increased progressively from patients achieving clinical remission to those"/>
 <result pre="CI 1.32â€&quot;2.15) or moderate (adjusted IRR 1.30, 95% CI 1.09â€&quot;1.56)" exact="disease" post="activity, demonstrating the importance of maintaining a good disease"/>
 <result pre="1.09â€&quot;1.56) disease activity, demonstrating the importance of maintaining a good" exact="disease" post="control in order to reduce infectious complications [33]. Another"/>
 <result pre="of maintaining a good disease control in order to reduce" exact="infectious" post="complications [33]. Another important determinant of infectious risk is"/>
 <result pre="order to reduce infectious complications [33]. Another important determinant of" exact="infectious" post="risk is the presence of comorbidities, which very often"/>
 <result pre="comorbidities, which very often complicate the course of RA [34]." exact="Diabetes mellitus," post="cardiovascular diseases, renal failure, interstitial lung disease, and chronic"/>
 <result pre="very often complicate the course of RA [34]. Diabetes mellitus," exact="cardiovascular" post="diseases, renal failure, interstitial lung disease, and chronic obstructive"/>
 <result pre="complicate the course of RA [34]. Diabetes mellitus, cardiovascular diseases," exact="renal failure," post="interstitial lung disease, and chronic obstructive pulmonary disease (COPD)"/>
 <result pre="course of RA [34]. Diabetes mellitus, cardiovascular diseases, renal failure," exact="interstitial lung disease," post="and chronic obstructive pulmonary disease (COPD) are all concomitant"/>
 <result pre="of RA [34]. Diabetes mellitus, cardiovascular diseases, renal failure, interstitial" exact="lung disease," post="and chronic obstructive pulmonary disease (COPD) are all concomitant"/>
 <result pre="Diabetes mellitus, cardiovascular diseases, renal failure, interstitial lung disease, and" exact="chronic" post="obstructive pulmonary disease (COPD) are all concomitant disorders associated"/>
 <result pre="cardiovascular diseases, renal failure, interstitial lung disease, and chronic obstructive" exact="pulmonary" post="disease (COPD) are all concomitant disorders associated with an"/>
 <result pre="diseases, renal failure, interstitial lung disease, and chronic obstructive pulmonary" exact="disease" post="(COPD) are all concomitant disorders associated with an increased"/>
 <result pre="renal failure, interstitial lung disease, and chronic obstructive pulmonary disease" exact="(COPD)" post="are all concomitant disorders associated with an increased incidence"/>
 <result pre="are all concomitant disorders associated with an increased incidence of" exact="infections" post="in RA [27,35]. Finally, RA can also be complicated"/>
 <result pre="in RA [27,35]. Finally, RA can also be complicated by" exact="infections" post="caused by the iatrogenic effect of immunosuppressive therapies, which"/>
 <result pre="in the next section. 4 The impact of drugs for" exact="rheumatic" post="diseases on viral infections: what do we know? 4.1"/>
 <result pre="section. 4 The impact of drugs for rheumatic diseases on" exact="viral" post="infections: what do we know? 4.1 Corticosteroids and NSAIDs"/>
 <result pre="as remission inducer and bridging therapy for the management of" exact="disease" post="flare has recently been renewed by the latest update"/>
 <result pre="downside is the broad spectrum of adverse events, including severe" exact="infections" post="and the high risk of developing comorbidities further increasing"/>
 <result pre="high risk of developing comorbidities further increasing the risk of" exact="infection" post="[27,38]. Although RCTs conducted in the past with CS"/>
 <result pre="in the past with CS showed no higher risk of" exact="infections" post="in RA patients [[39], [40], [41]], cohort and case-control"/>
 <result pre="[41]], cohort and case-control studies reported increased rates of overall" exact="infections" post="in RA patients treated with CS, according to a"/>
 <result pre="according to a dose-dependent fashion [42]. The majority of these" exact="infectious" post="events are of bacterial etiology, but RA patients receiving"/>
 <result pre="fashion [42]. The majority of these infectious events are of" exact="bacterial" post="etiology, but RA patients receiving CS exhibit a greater"/>
 <result pre="patients receiving CS exhibit a greater risk of developing even" exact="viral" post="infections. As an example, a 2012 retrospective cohort-study demonstrated"/>
 <result pre="example, a 2012 retrospective cohort-study demonstrated an increased risk of" exact="Herpes Zoster" post="infections with an incidence rate of 8.54 cases per"/>
 <result pre="a 2012 retrospective cohort-study demonstrated an increased risk of Herpes" exact="Zoster" post="infections with an incidence rate of 8.54 cases per"/>
 <result pre="2012 retrospective cohort-study demonstrated an increased risk of Herpes Zoster" exact="infections" post="with an incidence rate of 8.54 cases per 1000"/>
 <result pre="suppress the host inflammatory response, which in the case of" exact="viral" post="infections of the respiratory tract is the major responsible"/>
 <result pre="the host inflammatory response, which in the case of viral" exact="infections" post="of the respiratory tract is the major responsible for"/>
 <result pre="response, which in the case of viral infections of the" exact="respiratory" post="tract is the major responsible for lung damage and"/>
 <result pre="widely use of CS for the management of Middle East" exact="respiratory" post="syndrome (MERS)-CoV [44] and SARS-CoV [45] outbreaks, both histologically"/>
 <result pre="use of CS for the management of Middle East respiratory" exact="syndrome" post="(MERS)-CoV [44] and SARS-CoV [45] outbreaks, both histologically characterized"/>
 <result pre="(MERS)-CoV [44] and SARS-CoV [45] outbreaks, both histologically characterized by" exact="lung inflammation" post="and diffuse alveolar damage [46]. However, evidence from the"/>
 <result pre="SARS-CoV [45] outbreaks, both histologically characterized by lung inflammation and" exact="diffuse" post="alveolar damage [46]. However, evidence from the literature points"/>
 <result pre="1.75, 95% CI 1.3â€&quot;2.4; pÂ =Â .0002), increased rate of" exact="secondary" post="bacterial or fungal infection (RR 2Â·0, 95% CI 1Â·0â€&quot;3Â·8;"/>
 <result pre="95% CI 1.3â€&quot;2.4; pÂ =Â .0002), increased rate of secondary" exact="bacterial" post="or fungal infection (RR 2Â·0, 95% CI 1Â·0â€&quot;3Â·8; pÂ"/>
 <result pre="1.3â€&quot;2.4; pÂ =Â .0002), increased rate of secondary bacterial or" exact="fungal infection" post="(RR 2Â·0, 95% CI 1Â·0â€&quot;3Â·8; pÂ =Â .04), and"/>
 <result pre="pÂ =Â .0002), increased rate of secondary bacterial or fungal" exact="infection" post="(RR 2Â·0, 95% CI 1Â·0â€&quot;3Â·8; pÂ =Â .04), and"/>
 <result pre="review exploring treatments for ARDS, including six studies with a" exact="total" post="of 574 patients, concluded that insufficient evidence exists to"/>
 <result pre="no clear reason exists to expect that patients with COVID-19" exact="infection" post="will benefit from CS, and they might be more"/>
 <result pre="current interim guidance from WHO on clinical management of COVID-19" exact="infection" post="advises against the use of CS unless indicated for"/>
 <result pre="reason [10]. The role of NSAIDs in the course of" exact="viral" post="infections is still controversial. Ibuprofen has been demonstrated to"/>
 <result pre="[10]. The role of NSAIDs in the course of viral" exact="infections" post="is still controversial. Ibuprofen has been demonstrated to induce"/>
 <result pre="increase the susceptibility and worsen the clinical course of COVID-19" exact="infection" post="in treated patients [15]. In addition, the use of"/>
 <result pre="of the infection. 4.2 csDMARDs The most comprehensive analysis of" exact="infectious" post="risk in patients treated with csDMARDs is a retrospective,"/>
 <result pre="a population-based RA cohort using an administrative database including a" exact="total" post="of 27,710 individuals with RA and providing 162,710 person-years"/>
 <result pre="without corticosteroids was associated with a small decrease in mild" exact="infection" post="risk (adjusted rate ratio [RR] 0.90, 95% confidence interval"/>
 <result pre="[95% CI] 0.88â€&quot;0.93) and was not associated with increased serious" exact="infection" post="risk (adjusted RR 0.92, 95% CI 0.85â€&quot;1.0). Similarly, another"/>
 <result pre="a claim database demonstrated a slightly reduced risk of hospitalized" exact="infection" post="for methotrexate (adjusted RR 0.81, 95% CI 0.70â€&quot;0.93) and"/>
 <result pre="the literature confirmed the lack of an increased risk of" exact="infection" post="in patients receiving MTX (RR: 1.14; 95% CI, 0.98â€&quot;1.34)"/>
 <result pre="these reports provided no data on the risk of stratified" exact="infection" post="by pathogen. 4.3 bDMARDs The risk of infection observed"/>
 <result pre="of stratified infection by pathogen. 4.3 bDMARDs The risk of" exact="infection" post="observed in RA patients treated with bDMARDs is generally"/>
 <result pre="abatacept is accepted as the safest bDMARD in terms of" exact="infectious" post="risk [60,61]. Data focused on viral respiratory infections in"/>
 <result pre="bDMARD in terms of infectious risk [60,61]. Data focused on" exact="viral" post="respiratory infections in bDMARD cohort are still very limited."/>
 <result pre="in terms of infectious risk [60,61]. Data focused on viral" exact="respiratory" post="infections in bDMARD cohort are still very limited. The"/>
 <result pre="terms of infectious risk [60,61]. Data focused on viral respiratory" exact="infections" post="in bDMARD cohort are still very limited. The incidence"/>
 <result pre="bDMARD cohort are still very limited. The incidence of influenza-like" exact="infections" post="observed in a cohort of 159 Italian patients treated"/>
 <result pre="frequent [63]. 4.4 tsDMARDs The overall risk of serious and" exact="opportunistic infections" post="observed with Janus Kinase (JAK) inhibitors in RA patients"/>
 <result pre="[63]. 4.4 tsDMARDs The overall risk of serious and opportunistic" exact="infections" post="observed with Janus Kinase (JAK) inhibitors in RA patients"/>
 <result pre="use have raised the issue of an increased risk of" exact="Herpes Zoster" post="virus (HZV) infections [66]. Data from tofacitinib pooled population"/>
 <result pre="have raised the issue of an increased risk of Herpes" exact="Zoster" post="virus (HZV) infections [66]. Data from tofacitinib pooled population"/>
 <result pre="issue of an increased risk of Herpes Zoster virus (HZV)" exact="infections" post="[66]. Data from tofacitinib pooled population enrolled in RCTs"/>
 <result pre="1.40; 2.88) [69], and the risk of serious hospitalized HZV" exact="infection" post="is 2-fold higher versus all bDMARDs [70]. Older age,"/>
 <result pre="infection is 2-fold higher versus all bDMARDs [70]. Older age," exact="female" post="sex, prednisone &amp;gt;7.5Â mg/day, prior infection, and greater number"/>
 <result pre="with increased HZV risk, whereas vaccination was associated with a" exact="lower" post="risk [71]. More recent reports from RCTs conducted with"/>
 <result pre="confirmed the same trend, suggesting that the increase in HZV" exact="infections" post="can be considered as a class effect of JAKis"/>
 <result pre="downregulation of both cell-mediated immunity and innate antiviral signaling through" exact="type I" post="and II interferons (IFN) is likely to be involved"/>
 <result pre="[74]. Currently, no data are available on the risk of" exact="respiratory" post="virus infections carried by JAK inhibitors. 5 The management"/>
 <result pre="no data are available on the risk of respiratory virus" exact="infections" post="carried by JAK inhibitors. 5 The management of COVID-19:"/>
 <result pre="approved targeted therapeutics for the treatment of the new SARS-CoV-2" exact="infection" post="are still lacking and the management of COVID-19 is"/>
 <result pre="are now under investigation for the treatment of this emerging" exact="disease" post="[75]. The need to urgently identify an effective approach"/>
 <result pre="efficacy of the existing antiviral drugs commonly used for other" exact="viral" post="infections. In particular, considering the similarity between SARS-CoV-2 and"/>
 <result pre="cases have demonstrated the ability of lopinavir-ritonavir to significantly reduce" exact="viral" post="load and improve disease outcome [77]. In addition, remdesivir,"/>
 <result pre="ability of lopinavir-ritonavir to significantly reduce viral load and improve" exact="disease" post="outcome [77]. In addition, remdesivir, an adenosine analogue currently"/>
 <result pre="adenosine analogue currently under development for the management of Ebola" exact="virus infection" post="[78], has been recently recognized as a promising antiviral"/>
 <result pre="analogue currently under development for the management of Ebola virus" exact="infection" post="[78], has been recently recognized as a promising antiviral"/>
 <result pre="good preliminary in vitro results in the control of SARS-CoV-2" exact="infection" post="[80]. Consequently, lopinavir-ritonavir and remdesevir are currently the only"/>
 <result pre="consequence of the increased knowledge about the pathophysiology of the" exact="infection" post="(Table 1 ). Table 1 Potential role of anti-rheumatic"/>
 <result pre="definite criteria to identify patients to be treated Potential community-acquired" exact="pneumonia" post="due to immunosuppression Baricitinib Interference with viral penetration into"/>
 <result pre="treated Potential community-acquired pneumonia due to immunosuppression Baricitinib Interference with" exact="viral" post="penetration into the cell by blocking NAK-mediated endocytosis Impairment"/>
 <result pre="IFN anti-viral response Treatment of cytokine storm manifestations during ARDS" exact="Increased" post="risk of secondary HZV infections TNF-inhibitors Interference with viral"/>
 <result pre="Treatment of cytokine storm manifestations during ARDS Increased risk of" exact="secondary" post="HZV infections TNF-inhibitors Interference with viral penetration into the"/>
 <result pre="cytokine storm manifestations during ARDS Increased risk of secondary HZV" exact="infections" post="TNF-inhibitors Interference with viral penetration into the cell Slight"/>
 <result pre="ARDS Increased risk of secondary HZV infections TNF-inhibitors Interference with" exact="viral" post="penetration into the cell Slight increase in viral infection"/>
 <result pre="Interference with viral penetration into the cell Slight increase in" exact="viral infection" post="risk NSAIDs â€&quot; Facilitation of viral penetration by overexpression"/>
 <result pre="with viral penetration into the cell Slight increase in viral" exact="infection" post="risk NSAIDs â€&quot; Facilitation of viral penetration by overexpression"/>
 <result pre="Slight increase in viral infection risk NSAIDs â€&quot; Facilitation of" exact="viral" post="penetration by overexpression of ACE2 Delay in diagnosis due"/>
 <result pre="ACE2 Delay in diagnosis due to fever masking Corticosteroids â€&quot;" exact="Increased" post="risk of viral infection Increased mortality and risk of"/>
 <result pre="diagnosis due to fever masking Corticosteroids â€&quot; Increased risk of" exact="viral infection" post="Increased mortality and risk of secondary bacterial or fungal"/>
 <result pre="due to fever masking Corticosteroids â€&quot; Increased risk of viral" exact="infection" post="Increased mortality and risk of secondary bacterial or fungal"/>
 <result pre="to fever masking Corticosteroids â€&quot; Increased risk of viral infection" exact="Increased" post="mortality and risk of secondary bacterial or fungal infection"/>
 <result pre="Increased risk of viral infection Increased mortality and risk of" exact="secondary" post="bacterial or fungal infection ACE2Â =Â angiotensin converting enzyme"/>
 <result pre="risk of viral infection Increased mortality and risk of secondary" exact="bacterial" post="or fungal infection ACE2Â =Â angiotensin converting enzyme 2,"/>
 <result pre="viral infection Increased mortality and risk of secondary bacterial or" exact="fungal infection" post="ACE2Â =Â angiotensin converting enzyme 2, ARDSÂ =Â acute"/>
 <result pre="infection Increased mortality and risk of secondary bacterial or fungal" exact="infection" post="ACE2Â =Â angiotensin converting enzyme 2, ARDSÂ =Â acute"/>
 <result pre="fungal infection ACE2Â =Â angiotensin converting enzyme 2, ARDSÂ =Â" exact="acute" post="respiratory distress syndrome, NAKÂ =Â numb-associated kinase; HZVÂ =Â"/>
 <result pre="infection ACE2Â =Â angiotensin converting enzyme 2, ARDSÂ =Â acute" exact="respiratory" post="distress syndrome, NAKÂ =Â numb-associated kinase; HZVÂ =Â Herpes"/>
 <result pre="acute respiratory distress syndrome, NAKÂ =Â numb-associated kinase; HZVÂ =Â" exact="Herpes Zoster" post="virus, IFNÂ =Â interferon, NSAIDsÂ =Â nonsteroidal anti-inflammatory drugs."/>
 <result pre="respiratory distress syndrome, NAKÂ =Â numb-associated kinase; HZVÂ =Â Herpes" exact="Zoster" post="virus, IFNÂ =Â interferon, NSAIDsÂ =Â nonsteroidal anti-inflammatory drugs."/>
 <result pre="of pneumonia, promoting a virus negative conversion, and shortening the" exact="disease" post="course at different levels of severity [92]. More recently,"/>
 <result pre="to be the best option for the management of SARS-CoV-2" exact="infection" post="[93]. 5.2 IL-6 and IL-1 blockers As already described,"/>
 <result pre="already described, ARDS occurring in most severe case of COVID-19" exact="infection" post="is mainly produced by the massive release of pro-inflammatory"/>
 <result pre="by the massive release of pro-inflammatory mediators (CRS) associated with" exact="viral" post="replication and lung injury, leading to multiorgan failure [22]."/>
 <result pre="T-cells functionally exhausted [94]. Since an effective immune response against" exact="viral" post="infections depends on the activation of cytotoxic T cells,"/>
 <result pre="functionally exhausted [94]. Since an effective immune response against viral" exact="infections" post="depends on the activation of cytotoxic T cells, CRS"/>
 <result pre="cytotoxic T cells, CRS might be associated with a decreased" exact="viral" post="clearance, contributing to COVID-19 worsening. IL-6 and IL-1 play"/>
 <result pre="in China and is currently ongoing in patients with COVID-19" exact="pneumonia" post="and elevated IL-6 levels (ChiCTR2000029765) and a phase II"/>
 <result pre="Regulatory Drug Agency (AIFA) and will enrol 330 patients with" exact="pneumonia" post="and early respiratory failure, with 1-month mortality reduction as"/>
 <result pre="(AIFA) and will enrol 330 patients with pneumonia and early" exact="respiratory" post="failure, with 1-month mortality reduction as primary outcome (TOCIVID-19)."/>
 <result pre="pneumonia and early respiratory failure, with 1-month mortality reduction as" exact="primary" post="outcome (TOCIVID-19). Moreover, the company that produces the second"/>
 <result pre="The identification of a unique definition of CRS during COVID-19" exact="infection" post="is crucial to better customize the management of critical"/>
 <result pre="of minimum normal range), and increased levels of IL-6 in" exact="peripheral" post="blood have been recognized as the greatest risk factors"/>
 <result pre="factors of CRS in a retrospective analysis of 11 critically" exact="pneumonia" post="Chinese patients infected with COVID-19 [98]. Increasing ferritin level"/>
 <result pre="immunosuppressive treatment [22]. 5.3 TNF inhibitors As previously described, SARS-CoV" exact="infection" post="is associated with a downregulation of ACE2 expression coupled"/>
 <result pre="the renin-angiotensin system responsible for lung injury [14]. Moreover, the" exact="viral" post="spike protein is able to induce a TNF-Î±-converting enzyme"/>
 <result pre="of TNF inhibitors may be effective in reducing both SARS-CoV2" exact="infection" post="and the consequent organ damage [100]. As a result,"/>
 <result pre="[100]. As a result, a study evaluating adalimumab in COVID-19" exact="infection" post="has recently been registered in the Chinese Clinical Trial"/>
 <result pre="ruxolitinib, and fedratinib, which have all been demonstrated to inhibit" exact="infection" post="of cells by Dengue virus, Ebola virus, and respiratory"/>
 <result pre="have all been demonstrated to inhibit infection of cells by" exact="Dengue" post="virus, Ebola virus, and respiratory syncytial virus [103]. Unfortunately,"/>
 <result pre="inhibit infection of cells by Dengue virus, Ebola virus, and" exact="respiratory" post="syncytial virus [103]. Unfortunately, all these compounds are able"/>
 <result pre="interferon gamma) responsible for the more severe forms of interstitial" exact="pneumonia" post="during COVID-19 [107,108]. Finally, the minimal interaction of baricitinib"/>
 <result pre="one of the most potent innate immune responses to prevent" exact="viral" post="replication during the early phases of infection [110]. The"/>
 <result pre="responses to prevent viral replication during the early phases of" exact="infection" post="[110]. The activation of transcription through JAK/STAT signaling pathway"/>
 <result pre="all viruses have developed strategies to combat the effects of" exact="type 1" post="and type 3 IFNs by blocking the IFN signaling"/>
 <result pre="developed strategies to combat the effects of type 1 and" exact="type 3" post="IFNs by blocking the IFN signaling pathway [112] and"/>
 <result pre="3 IFNs by blocking the IFN signaling pathway [112] and" exact="viral" post="encoded factors able to antagonize the JAK/STAT pathway are"/>
 <result pre="with a potential facilitating effect on the progression of SARS-CoV2" exact="infection" post="at the moment not yet better quantified. In conclusion,"/>
 <result pre="the possible use of baricitinib in the treatment of COVID-19" exact="infection" post="remains highly controversial and further studies are warranted to"/>
 <result pre="potential role in the treatment of more serious cases of" exact="viral pneumonia." post="6 Conclusions The COVID-19 epidemic represents a health emergency"/>
 <result pre="emergency that is inevitably affecting the management of a complex" exact="disease" post="such as RA [115,116]. As a chronic autoimmune inflammatory"/>
 <result pre="of a complex disease such as RA [115,116]. As a" exact="chronic" post="autoimmune inflammatory disorder, RA carries a higher infectious risk"/>
 <result pre="a complex disease such as RA [115,116]. As a chronic" exact="autoimmune" post="inflammatory disorder, RA carries a higher infectious risk than"/>
 <result pre="As a chronic autoimmune inflammatory disorder, RA carries a higher" exact="infectious" post="risk than the general population. The use of synthetic"/>
 <result pre="incidence of serious infections, but the poor control of RA" exact="disease" post="activity is an even greater infectious risk factor. Thus,"/>
 <result pre="poor control of RA disease activity is an even greater" exact="infectious" post="risk factor. Thus, RA patients should be encouraged to"/>
 <result pre="opinion, this strategy is reasonable as it aims to prevent" exact="disease" post="flares that can contributes to increase patient burden, disability,"/>
 <result pre="as bridging therapy, which may further increase the risk of" exact="viral infection," post="as well as being inappropriate for the management of"/>
 <result pre="included in the treatment protocol for the management of COVID-19" exact="infections" post="and might be useful to prevent or mitigate the"/>
 <result pre="might be useful to prevent or mitigate the course of" exact="infection" post="in patients with RA taking them as csDMARDs. The"/>
 <result pre="promising for the management of most critical cases of interstitial" exact="pneumonia" post="complicated by CRS, but the identification of definite criteria"/>
 <result pre="although baricitinib has the potential to affect SARS-CoV2 penetration into" exact="pulmonary" post="epithelial cells, major concerns remain about the inhibition of"/>
 <result pre="baricitinib has the potential to affect SARS-CoV2 penetration into pulmonary" exact="epithelial" post="cells, major concerns remain about the inhibition of IFNs"/>
 <result pre="IFNs activity which could be detrimental in the course of" exact="viral infection." post="References References 1ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.A pneumonia outbreak associated with a new"/>
 <result pre="detrimental in the course of viral infection. References References 1ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="Sci Rev202010.1093/nsr/nwaa036 3WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJama323202010.1001/jama.2020.2648 4ZhangJ.-J.DongX.CaoY.-Y.YuanY.-D.YangY.-B.YanY.-Q.Clinical characteristics of 140 patients infected"/>
 <result pre="infected by SARS-CoV-2 in Wuhan, ChinaAllergy202010.1111/all.14238 5GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaNew Engl J Medicine202010.1056/nejmoa2002032 6HuangC.WangY.LiX.RenL.ZhaoJ.HuY.Clinical features of"/>
 <result pre="7YangX.YuY.XuJ.ShuH.XiaJ.LiuH.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
 <result pre="Med202010.1016/s2213-2600(20)30079-5 8https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd(Accessed 17th March 2020) 9FavalliE.G.BiggioggeroM.MeroniP.L.Methotrexate for the treatment of" exact="rheumatoid arthritis" post="in the biologic era: still an â€œanchorâ€� drug?Autoimmun Rev1320141102110810.1016/j.autrev.2014.08.02625172238"/>
 <result pre="8https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd(Accessed 17th March 2020) 9FavalliE.G.BiggioggeroM.MeroniP.L.Methotrexate for the treatment of rheumatoid" exact="arthritis" post="in the biologic era: still an â€œanchorâ€� drug?Autoimmun Rev1320141102110810.1016/j.autrev.2014.08.02625172238"/>
 <result pre="still an â€œanchorâ€� drug?Autoimmun Rev1320141102110810.1016/j.autrev.2014.08.02625172238 10World Health OrganizationClinical Management of" exact="Severe" post="Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is"/>
 <result pre="an â€œanchorâ€� drug?Autoimmun Rev1320141102110810.1016/j.autrev.2014.08.02625172238 10World Health OrganizationClinical Management of Severe" exact="Acute" post="Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection is Suspected:"/>
 <result pre="â€œanchorâ€� drug?Autoimmun Rev1320141102110810.1016/j.autrev.2014.08.02625172238 10World Health OrganizationClinical Management of Severe Acute" exact="Respiratory" post="Infection When Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim"/>
 <result pre="drug?Autoimmun Rev1320141102110810.1016/j.autrev.2014.08.02625172238 10World Health OrganizationClinical Management of Severe Acute Respiratory" exact="Infection" post="When Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance2020"/>
 <result pre="Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV)" exact="Infection" post="is Suspected: Interim Guidance2020 11TisoncikJ.R.KorthM.J.SimmonsC.P.FarrarJ.MartinT.R.KatzeM.G.Into the eye of the"/>
 <result pre="receptor of Wuhan 2019-nCovBiorxiv20201202026.91998510.1101/2020.01.26.919985 14ZouZ.YanY.ShuY.GaoR.SunY.LiX.Angiotensin-converting enzyme 2 protects from lethal" exact="avian influenza" post="a H5N1 infectionsNat Commun52014359410.1038/ncomms459424800825 15FangL.KarakiulakisG.RothM.Are patients with hypertension and"/>
 <result pre="lethal avian influenza a H5N1 infectionsNat Commun52014359410.1038/ncomms459424800825 15FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="influenza a H5N1 infectionsNat Commun52014359410.1038/ncomms459424800825 15FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med202010.1016/s2213-2600(20)30116-8 16G"/>
 <result pre="Cardiology ES o. Position Statement of the ESC Council on" exact="Hypertension" post="on ACE-Inhibitors and Angiotensin Receptor Blockers n.d. 17LiX.GengM.PengY.MengL.LuS.Molecular immune"/>
 <result pre="with hemophagocytic lymphohistiocytosisChest14920161294130110.1016/j.chest.2015.11.00426836913 21WanS.YiQ.FanS.LvJ.ZhangX.GuoL.Characteristics of lymphocyte subsets and cytokines in" exact="peripheral" post="blood of 123 hospitalized patients with 2019 novel coronavirus"/>
 <result pre="peripheral blood of 123 hospitalized patients with 2019 novel coronavirus" exact="pneumonia" post="(NCP)Medrxiv202010.1101/2020.02.10.20021832 22MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: consider cytokine storm syndromes and immunosuppressionLancet202010.1016/S0140-6736(20)30628-0 23MathewA.J.RavindranV.Infections"/>
 <result pre="arthritisBest Pract Res Clin Rheumatol28201493595910.1016/j.berh.2015.04.00926096095 24BogdanosD.P.SmykD.S.InvernizziP.RigopoulouE.I.BlankM.PouriaS.Infectome: a platform to trace" exact="infectious" post="triggers of autoimmunityAutoimmun Rev12201272674010.1016/j.autrev.2012.12.00523266520 25ArleevskayaM.I.ShafigullinaA.Z.FilinaY.V.LemerleJ.RenaudineauY.Associations between viral infection history"/>
 <result pre="platform to trace infectious triggers of autoimmunityAutoimmun Rev12201272674010.1016/j.autrev.2012.12.00523266520 25ArleevskayaM.I.ShafigullinaA.Z.FilinaY.V.LemerleJ.RenaudineauY.Associations between" exact="viral infection" post="history symptoms, granulocyte reactive oxygen species activity, and active"/>
 <result pre="to trace infectious triggers of autoimmunityAutoimmun Rev12201272674010.1016/j.autrev.2012.12.00523266520 25ArleevskayaM.I.ShafigullinaA.Z.FilinaY.V.LemerleJ.RenaudineauY.Associations between viral" exact="infection" post="history symptoms, granulocyte reactive oxygen species activity, and active"/>
 <result pre="infection history symptoms, granulocyte reactive oxygen species activity, and active" exact="rheumatoid arthritis" post="disease in untreated women at onset: results from a"/>
 <result pre="history symptoms, granulocyte reactive oxygen species activity, and active rheumatoid" exact="arthritis" post="disease in untreated women at onset: results from a"/>
 <result pre="symptoms, granulocyte reactive oxygen species activity, and active rheumatoid arthritis" exact="disease" post="in untreated women at onset: results from a longitudinal"/>
 <result pre="from a longitudinal cohort study of Tatarstan womenFront Immunol82017172510.3389/fimmu.2017.0172529259607 26JooY.B.LimY.-H.KimK.-J.ParkK.-S.ParkY.-J.Respiratory" exact="viral" post="infections and the risk of rheumatoid arthritisArthritis Res Ther21201919910.1186/s13075-019-1977-931470887"/>
 <result pre="a longitudinal cohort study of Tatarstan womenFront Immunol82017172510.3389/fimmu.2017.0172529259607 26JooY.B.LimY.-H.KimK.-J.ParkK.-S.ParkY.-J.Respiratory viral" exact="infections" post="and the risk of rheumatoid arthritisArthritis Res Ther21201919910.1186/s13075-019-1977-931470887 27ListingJ.GerholdK.ZinkA.The"/>
 <result pre="the risk of rheumatoid arthritisArthritis Res Ther21201919910.1186/s13075-019-1977-931470887 27ListingJ.GerholdK.ZinkA.The risk of" exact="infections" post="associated with rheumatoid arthritis, with its comorbidity and treatmentRheumatology"/>
 <result pre="rheumatoid arthritisArthritis Res Ther21201919910.1186/s13075-019-1977-931470887 27ListingJ.GerholdK.ZinkA.The risk of infections associated with" exact="rheumatoid arthritis," post="with its comorbidity and treatmentRheumatology (Oxford)522012536110.1093/rheumatology/kes30523192911 28GallowayJ.B.HyrichK.L.MercerL.K.DixonW.G.FuB.UstianowskiA.P.Anti-TNF therapy is"/>
 <result pre="28GallowayJ.B.HyrichK.L.MercerL.K.DixonW.G.FuB.UstianowskiA.P.Anti-TNF therapy is associated with an increased risk of serious" exact="infections" post="in patients with rheumatoid arthritis especially in the first"/>
 <result pre="with an increased risk of serious infections in patients with" exact="rheumatoid arthritis" post="especially in the first 6 months of treatment: updated"/>
 <result pre="an increased risk of serious infections in patients with rheumatoid" exact="arthritis" post="especially in the first 6 months of treatment: updated"/>
 <result pre="with special emphasis on risks in the elderlyRheumatology (Oxford)50201012413110.1093/rheumatology/keq24220675706 29WiddifieldJ.BernatskyS.PatersonJ.M.GunrajN.ThorneJ.C.PopeJ.Serious" exact="infections" post="in a population-based cohort of 86,039 seniors with rheumatoid"/>
 <result pre="of 86,039 seniors with rheumatoid arthritisArthritis Care Res65201335336110.1002/acr.21812 30DoranM.F.CrowsonC.S.PondG.R.Oâ€™FallonW.M.GabrielS.E.Frequency of" exact="infection" post="in patients with rheumatoid arthritis compared with controls: a"/>
 <result pre="rheumatoid arthritisArthritis Care Res65201335336110.1002/acr.21812 30DoranM.F.CrowsonC.S.PondG.R.Oâ€™FallonW.M.GabrielS.E.Frequency of infection in patients with" exact="rheumatoid arthritis" post="compared with controls: a population-based studyArthritis Rheum4620022287229310.1002/art.1052412355475 31FranklinJ.LuntM.BunnD.SymmonsD.P.M.SilmanA.J.Risk and"/>
 <result pre="arthritisArthritis Care Res65201335336110.1002/acr.21812 30DoranM.F.CrowsonC.S.PondG.R.Oâ€™FallonW.M.GabrielS.E.Frequency of infection in patients with rheumatoid" exact="arthritis" post="compared with controls: a population-based studyArthritis Rheum4620022287229310.1002/art.1052412355475 31FranklinJ.LuntM.BunnD.SymmonsD.P.M.SilmanA.J.Risk and"/>
 <result pre="with controls: a population-based studyArthritis Rheum4620022287229310.1002/art.1052412355475 31FranklinJ.LuntM.BunnD.SymmonsD.P.M.SilmanA.J.Risk and predictors of" exact="infection" post="leading to hospitalisation in a large primary-care-derived cohort of"/>
 <result pre="primary-care-derived cohort of patients with inflammatory polyarthritisAnn Rheum Dis66200730831210.1136/ard.2006.05726516984941 32AuK.ReedG.CurtisJ.R.KremerJ.M.GreenbergJ.D.StrandV.High" exact="disease" post="activity is associated with an increased risk of infection"/>
 <result pre="32AuK.ReedG.CurtisJ.R.KremerJ.M.GreenbergJ.D.StrandV.High disease activity is associated with an increased risk of" exact="infection" post="in patients with rheumatoid arthritisAnn Rheum Dis70201178579110.1136/ard.2010.12863721288960 33AccorttN.A.LesperanceT.LiuM.RebelloS.TrivediM.LiY.Impact of"/>
 <result pre="Dis70201178579110.1136/ard.2010.12863721288960 33AccorttN.A.LesperanceT.LiuM.RebelloS.TrivediM.LiY.Impact of sustained remission on the risk of serious" exact="infection" post="in patients with rheumatoid arthritisArthritis Care Res70201867968410.1002/acr.23426 34DougadosM.SoubrierM.AntunezA.BalintP.BalsaA.BuchM.H.Prevalence of"/>
 <result pre="patients with rheumatoid arthritisArthritis Care Res70201867968410.1002/acr.23426 34DougadosM.SoubrierM.AntunezA.BalintP.BalsaA.BuchM.H.Prevalence of comorbidities in" exact="rheumatoid arthritis" post="and evaluation of their monitoring: results of an international,"/>
 <result pre="with rheumatoid arthritisArthritis Care Res70201867968410.1002/acr.23426 34DougadosM.SoubrierM.AntunezA.BalintP.BalsaA.BuchM.H.Prevalence of comorbidities in rheumatoid" exact="arthritis" post="and evaluation of their monitoring: results of an international,"/>
 <result pre="patients with rheumatoid arthritisRheumatology5220131809181710.1093/rheumatology/ket22423813577 36SmolenJ.S.LandewÃ©R.B.M.BijlsmaJ.W.J.BurmesterG.R.DougadosM.KerschbaumerA.EULAR recommendations for the management of" exact="rheumatoid arthritis" post="with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnn"/>
 <result pre="with rheumatoid arthritisRheumatology5220131809181710.1093/rheumatology/ket22423813577 36SmolenJ.S.LandewÃ©R.B.M.BijlsmaJ.W.J.BurmesterG.R.DougadosM.KerschbaumerA.EULAR recommendations for the management of rheumatoid" exact="arthritis" post="with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateAnn"/>
 <result pre="strategy for early rheumatoid arthritisAnn Intern Med156201232910.7326/0003-4819-156-5-201203060-0000422393128 42DixonW.G.SuissaS.HudsonM.The association between" exact="systemic" post="glucocorticoid therapy and the risk of infection in patients"/>
 <result pre="42DixonW.G.SuissaS.HudsonM.The association between systemic glucocorticoid therapy and the risk of" exact="infection" post="in patients with rheumatoid arthritis: systematic review and meta-analysesArthritis"/>
 <result pre="protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe" exact="acute" post="respiratory syndromeClin Chem5120052333234010.1373/clinchem.2005.05446016195357 44ArabiY.M.MandourahY.Al-HameedF.SindiA.A.AlmekhlafiG.A.HusseinM.A.Corticosteroid therapy for critically ill patients"/>
 <result pre="(CXCL-10) and other chemokines predicts adverse outcome in severe acute" exact="respiratory" post="syndromeClin Chem5120052333234010.1373/clinchem.2005.05446016195357 44ArabiY.M.MandourahY.Al-HameedF.SindiA.A.AlmekhlafiG.A.HusseinM.A.Corticosteroid therapy for critically ill patients with"/>
 <result pre="Chem5120052333234010.1373/clinchem.2005.05446016195357 44ArabiY.M.MandourahY.Al-HameedF.SindiA.A.AlmekhlafiG.A.HusseinM.A.Corticosteroid therapy for critically ill patients with Middle East" exact="respiratory" post="syndromeAm J Resp Crit Care197201875776710.1164/rccm.201706-1172oc 45StockmanL.J.BellamyR.GarnerP.SARS: systematic review of"/>
 <result pre="Care197201875776710.1164/rccm.201706-1172oc 45StockmanL.J.BellamyR.GarnerP.SARS: systematic review of treatment effectsPLoS Med32006e34310.1371/journal.pmed.0030343 46MemishZ.A.PerlmanS.KerkhoveM.D.V.ZumlaA.Middle East" exact="respiratory" post="syndromeLancet Lond Engl202010.1016/s0140-6736(19)33221-0 47NiY.-N.ChenG.SunJ.LiangB.-M.LiangZ.-A.The effect of corticosteroids on mortality"/>
 <result pre="systematic review and meta-analysisCrit Care2320199910.1186/s13054-019-2395-830917856 48LewisS.R.PritchardM.W.ThomasC.M.SmithA.F.Pharmacological agents for adults with" exact="acute" post="respiratory distress syndromeCochrane Database Syst Rev72019CD00447710.1002/14651858.cd004477.pub3 49RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does"/>
 <result pre="review and meta-analysisCrit Care2320199910.1186/s13054-019-2395-830917856 48LewisS.R.PritchardM.W.ThomasC.M.SmithA.F.Pharmacological agents for adults with acute" exact="respiratory" post="distress syndromeCochrane Database Syst Rev72019CD00447710.1002/14651858.cd004477.pub3 49RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not"/>
 <result pre="ratsCardiology13120159710610.1159/00037536225896805 51LacailleD.GuhD.P.AbrahamowiczM.AnisA.H.EsdaileJ.M.Use of nonbiologic disease-modifying antirheumatic drugs and risk of" exact="infection" post="in patients with rheumatoid arthritisArthritis Rheum5920081074108110.1002/art.2391318668604 52SmittenA.L.ChoiH.K.HochbergM.C.SuissaS.SimonT.A.TestaM.A.The risk of"/>
 <result pre="in patients with rheumatoid arthritisArthritis Rheum5920081074108110.1002/art.2391318668604 52SmittenA.L.ChoiH.K.HochbergM.C.SuissaS.SimonT.A.TestaM.A.The risk of hospitalized" exact="infection" post="in patients with rheumatoid arthritisJ Rheumatol35200838739318260176 53IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of infection"/>
 <result pre="hospitalized infection in patients with rheumatoid arthritisJ Rheumatol35200838739318260176 53IbrahimA.AhmedM.ConwayR.CareyJ.J.Risk of" exact="infection" post="with methotrexate therapy in inflammatory diseases: a systematic review"/>
 <result pre="and meta-analysisJ Clin Med820181510.3390/jcm8010015 54TudesqJ.-J.CartronG.RiviÃ¨reS.MorquinD.IordacheL.MahrA.Clinical and microbiological characteristics of the" exact="infections" post="in patients treated with rituximab for autoimmune and/or malignant"/>
 <result pre="characteristics of the infections in patients treated with rituximab for" exact="autoimmune" post="and/or malignant hematological disordersAutoimmun Rev17201811512410.1016/j.autrev.2017.11.01529180125 55RamiroS.SeprianoA.ChatzidionysiouK.NamJ.L.SmolenJ.S.van der HeijdeD.Safety of"/>
 <result pre="the infections in patients treated with rituximab for autoimmune and/or" exact="malignant" post="hematological disordersAutoimmun Rev17201811512410.1016/j.autrev.2017.11.01529180125 55RamiroS.SeprianoA.ChatzidionysiouK.NamJ.L.SmolenJ.S.van der HeijdeD.Safety of synthetic and"/>
 <result pre="EULAR recommendations for management of rheumatoid arthritisAnn Rheum Dis7620171101113610.1136/annrheumdis-2016-21070828298374 56FavalliE.G.DesiatiF.AtzeniF.Sarzi-PuttiniP.CaporaliR.PallaviciniF.B.Serious" exact="infections" post="during anti-TNFÎ± treatment in rheumatoid arthritis patientsAutoimmun Rev8200926627310.1016/j.autrev.2008.11.00219022409 57AtzeniF.Sarzi-PuttiniP.BotsiosC.CarlettoA.CiprianiP.FavalliE.G.Long-term"/>
 <result pre="rheumatoid arthritisAnn Rheum Dis7620171101113610.1136/annrheumdis-2016-21070828298374 56FavalliE.G.DesiatiF.AtzeniF.Sarzi-PuttiniP.CaporaliR.PallaviciniF.B.Serious infections during anti-TNFÎ± treatment in" exact="rheumatoid arthritis" post="patientsAutoimmun Rev8200926627310.1016/j.autrev.2008.11.00219022409 57AtzeniF.Sarzi-PuttiniP.BotsiosC.CarlettoA.CiprianiP.FavalliE.G.Long-term anti-TNF therapy and the risk of"/>
 <result pre="arthritisAnn Rheum Dis7620171101113610.1136/annrheumdis-2016-21070828298374 56FavalliE.G.DesiatiF.AtzeniF.Sarzi-PuttiniP.CaporaliR.PallaviciniF.B.Serious infections during anti-TNFÎ± treatment in rheumatoid" exact="arthritis" post="patientsAutoimmun Rev8200926627310.1016/j.autrev.2008.11.00219022409 57AtzeniF.Sarzi-PuttiniP.BotsiosC.CarlettoA.CiprianiP.FavalliE.G.Long-term anti-TNF therapy and the risk of"/>
 <result pre="patientsAutoimmun Rev8200926627310.1016/j.autrev.2008.11.00219022409 57AtzeniF.Sarzi-PuttiniP.BotsiosC.CarlettoA.CiprianiP.FavalliE.G.Long-term anti-TNF therapy and the risk of serious" exact="infections" post="in a cohort of patients with rheumatoid arthritis: comparison"/>
 <result pre="adalimumab, etanercept and infliximab in the GISEA registryAutoimmun Rev12201222522910.1016/j.autrev.2012.06.00822796281 58RutherfordA.I.SubesingheS.HyrichK.L.GallowayJ.B.Serious" exact="infection" post="across biologic-treated patients with rheumatoid arthritis: results from the"/>
 <result pre="Biologics Register for Rheumatoid ArthritisAnn Rheum Dis77201890591010.1136/annrheumdis-2017-21282529592917 59SinghJ.A.CameronC.NoorbaloochiS.CullisT.TuckerM.ChristensenR.Risk of serious" exact="infection" post="in biological treatment of patients with rheumatoid arthritis: a"/>
 <result pre="of influenza-like illness into a cohort of patients affected by" exact="chronic" post="inflammatory rheumatism and treated with biological agentsReumatismo64201229930610.4081/reumatismo.2012.29923256105 63ShaleM.CzubM.KaplanG.G.PanaccioneR.GhoshS.Anti-tumor necrosis"/>
 <result pre="molecules), pros and cons of two different approaches to the" exact="disease" post="modifying treatment in rheumatoid arthritisAutoimmun Rev19201910242110.1016/j.autrev.2019.10242131733368 66FavalliE.G.Tofacitinibâ€™s infectious profile:"/>
 <result pre="to the disease modifying treatment in rheumatoid arthritisAutoimmun Rev19201910242110.1016/j.autrev.2019.10242131733368 66FavalliE.G.Tofacitinibâ€™s" exact="infectious" post="profile: concerns for clinical practiceLancet Rheumatol22020e65e6710.1016/S2665-9913(20)30001-1 67WinthropK.L.YamanakaH.ValdezH.MortensenE.ChewR.KrishnaswamiS.Herpes zoster and"/>
 <result pre="Rev19201910242110.1016/j.autrev.2019.10242131733368 66FavalliE.G.Tofacitinibâ€™s infectious profile: concerns for clinical practiceLancet Rheumatol22020e65e6710.1016/S2665-9913(20)30001-1 67WinthropK.L.YamanakaH.ValdezH.MortensenE.ChewR.KrishnaswamiS.Herpes" exact="zoster" post="and Tofacitinib therapy in patients with rheumatoid arthritisArthritis Rheum6620142675268410.1002/art.38745"/>
 <result pre="arthritisArthritis Rheum6620142675268410.1002/art.38745 68SmolenJ.S.GenoveseM.C.TakeuchiT.HyslopD.L.MaciasW.L.RooneyT.Safety profile of Baricitinib in patients with active" exact="rheumatoid arthritis" post="with over 2 years median time in treatmentJ Rheumatol46201871810.3899/jrheum.17136130219772"/>
 <result pre="Rheum6620142675268410.1002/art.38745 68SmolenJ.S.GenoveseM.C.TakeuchiT.HyslopD.L.MaciasW.L.RooneyT.Safety profile of Baricitinib in patients with active rheumatoid" exact="arthritis" post="with over 2 years median time in treatmentJ Rheumatol46201871810.3899/jrheum.17136130219772"/>
 <result pre="years median time in treatmentJ Rheumatol46201871810.3899/jrheum.17136130219772 69CurtisJ.R.XieF.YunH.BernatskyS.WinthropK.L.Real-world comparative risks of" exact="herpes" post="virus infections in tofacitinib and biologic-treated patients with rheumatoid"/>
 <result pre="time in treatmentJ Rheumatol46201871810.3899/jrheum.17136130219772 69CurtisJ.R.XieF.YunH.BernatskyS.WinthropK.L.Real-world comparative risks of herpes virus" exact="infections" post="in tofacitinib and biologic-treated patients with rheumatoid arthritisAnn Rheum"/>
 <result pre="arthritisAnn Rheum Dis7520161843184710.1136/annrheumdis-2016-20913127113415 70PawarA.DesaiR.J.GautamN.KimS.C.Risk of admission to hospital for serious" exact="infection" post="after initiating tofacitinib versus biologic DMARDs in patients with"/>
 <result pre="of rheumatoid arthritisDrugs Context8201921259510.7573/dic.21259531692920 73JamillouxY.JammalT.E.VuittonL.Gerfaud-ValentinM.KereverS.SÃ¨veP.JAK inhibitors for the treatment of" exact="autoimmune" post="and inflammatory diseasesAutoimmun Rev18201910239010.1016/j.autrev.2019.10239031520803 74WinthropK.L.The emerging safety profile of"/>
 <result pre="diseasesAutoimmun Rev18201910239010.1016/j.autrev.2019.10239031520803 74WinthropK.L.The emerging safety profile of JAK inhibitors in" exact="rheumatic" post="diseaseNat Rev Rheumatol13201723424310.1038/nrrheum.2017.2328250461 75LiuC.ZhouQ.LiY.GarnerL.V.WatkinsS.P.CarterL.J.Research and Development on therapeutic agents"/>
 <result pre="agents and vaccines for COVID-19 and related human coronavirus diseasesAcs" exact="Central" post="Sci202010.1021/acscentsci.0c00272 76ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.-Y.Coronaviruses - drug discovery and therapeutic optionsNat Rev"/>
 <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of Lopinavir/ritonavir for the treatment"/>
 <result pre="the application of Lopinavir/ritonavir for the treatment of COVID-19 infected" exact="pneumonia" post="monitored by quantitative RT-PCRJ Korean Med Sci352020e7910.3346/jkms.2020.35.e79 78MulanguS.DoddL.E.DaveyR.T.MbayaO.T.ProschanM.MukadiD.A randomized,"/>
 <result pre="Korean Med Sci352020e7910.3346/jkms.2020.35.e79 78MulanguS.DoddL.E.DaveyR.T.MbayaO.T.ProschanM.MukadiD.A randomized, controlled trial of Ebola virus" exact="disease" post="therapeuticsNew Engl J Medicine38120192293230310.1056/nejmoa1910993 79SheahanT.P.SimsA.C.GrahamR.L.MenacheryV.D.GralinskiL.E.CaseJ.B.Broad-spectrum antiviral GS-5734 inhibits both"/>
 <result pre="non-steroidal anti-inflammatory drugsJ Gen Virol4196920321410.1099/0022-1317-4-2-2034306296 85KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM.V.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Bioph Res Co323200426426810.1016/j.bbrc.2004.08.085 86PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.Chloroquine"/>
 <result pre="anti-inflammatory drugsJ Gen Virol4196920321410.1099/0022-1317-4-2-2034306296 85KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM.V.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Bioph Res Co323200426426810.1016/j.bbrc.2004.08.085 86PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.Chloroquine for"/>
 <result pre="drugsJ Gen Virol4196920321410.1099/0022-1317-4-2-2034306296 85KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM.V.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Bioph Res Co323200426426810.1016/j.bbrc.2004.08.085 86PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.Chloroquine for influenza"/>
 <result pre="trialLancet Infect Dis11201167768310.1016/s1473-3099(11)70065-221550310 87RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.Paradoxical effect of chloroquine treatment in enhancing" exact="chikungunya" post="virus infectionViruses10201826810.3390/v10050268 88VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS"/>
 <result pre="virus infectionViruses10201826810.3390/v10050268 88VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056910.1186/1743-422x-2-6916115318 89DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New insights on the antiviral effects"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends202010.5582/bst.2020.01047 93YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.In vitro antiviral activity and"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237 94DiaoB.WangC.TanY.ChenX.LiuY.NingL.Reduction and"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237 94DiaoB.WangC.TanY.ChenX.LiuY.NingL.Reduction and functional"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis202010.1093/cid/ciaa237 94DiaoB.WangC.TanY.ChenX.LiuY.NingL.Reduction and functional exhaustion"/>
 <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19)Medrxiv202010.1101/2020.02.18.20024364 95ShakooryB.CarcilloJ.A.ChathamW.W.AmdurR.L.ZhaoH.DinarelloC.A.Interleukin-1 receptor blockade is associated with reduced"/>
 <result pre="definition and risks of cytokine release syndrome-like in 11 COVID-19-infected" exact="pneumonia" post="critically ill patients: disease characteristics and retrospective analysisMedrxiv202010.1101/2020.02.26.20026989 99HagaS.YamamotoN.Nakai-MurakamiC.OsawaY.TokunagaK.SataT.Modulation"/>
 <result pre="cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients:" exact="disease" post="characteristics and retrospective analysisMedrxiv202010.1101/2020.02.26.20026989 99HagaS.YamamotoN.Nakai-MurakamiC.OsawaY.TokunagaK.SataT.Modulation of TNF-alpha-converting enzyme by"/>
 <result pre="protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates" exact="viral" post="entryProc Natl Acad Sci U S A10520087809781410.1073/pnas.071124110518490652 100WangW.YeL.YeL.LiB.GaoB.ZengY.Up-regulation of"/>
 <result pre="and receptor bindingLancet Lond Engl395202056557410.1016/s0140-6736(20)30251-8 103BekermanE.NeveuG.ShullaA.BrannanJ.PuS.-Y.WangS.Anticancer kinase inhibitors impair intracellular" exact="viral" post="trafficking and exert broad-spectrum antiviral effectsJ Clin Invest12720171338135210.1172/jci8985728240606 104StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.SmithD.COVID-19:"/>
 <result pre="for dengue treatmentAntiviral Res1552018677510.1016/j.antiviral.2018.05.00129753658 106RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet Lond Engl3952020e30e3110.1016/s0140-6736(20)30304-4 107FergusonF.M.GrayN.S.Kinase inhibitors: the road aheadNat"/>
 <result pre="dengue treatmentAntiviral Res1552018677510.1016/j.antiviral.2018.05.00129753658 106RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet Lond Engl3952020e30e3110.1016/s0140-6736(20)30304-4 107FergusonF.M.GrayN.S.Kinase inhibitors: the road aheadNat Rev"/>
 <result pre="autoinflammatory interferonopathiesJ Clin Invest12820183041305210.1172/jci9881429649002 109VirtanenA.T.HaikarainenT.RaivolaJ.SilvennoinenO.Selective JAKinibs: prospects in inflammatory and" exact="autoimmune" post="diseasesBiodrugs Clin Immunother Biopharm Gene Ther332019153210.1007/s40259-019-00333-w 110BordenE.C.SenG.C.UzeG.SilvermanR.H.RansohoffR.M.FosterG.R.Interferons at age"/>
 <result pre="a diverse range of gene products are effectors of the" exact="type I" post="interferon antiviral responseNature525201514410.1038/nature14554 112FlemingS.Viral inhibition of the IFN-induced JAK/STAT"/>
 <result pre="practice and future perspectivesAutoimmun Rev1620171185119510.1016/j.autrev.2017.10.00229037899 117EdwardsC.J.GaleazziM.BellinviaS.RingerA.DimitroulasT.KitasG.Can we wean patients with" exact="inflammatory arthritis" post="from biological therapies?Autoimmun Rev18201910239910.1016/j.autrev.2019.10239931639516"/>
 <result pre="and future perspectivesAutoimmun Rev1620171185119510.1016/j.autrev.2017.10.00229037899 117EdwardsC.J.GaleazziM.BellinviaS.RingerA.DimitroulasT.KitasG.Can we wean patients with inflammatory" exact="arthritis" post="from biological therapies?Autoimmun Rev18201910239910.1016/j.autrev.2019.10239931639516"/>
</results>
